Jeff Jones
Stock Analyst at Oppenheimer
(1.91)
# 2,005
Out of 4,479 analysts
58
Total ratings
22.22%
Success rate
-0.34%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Reiterates: Outperform | $2 → $19 | $10.49 | +81.12% | 4 | Jun 18, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Perform | n/a | $0.70 | - | 4 | Jun 7, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Outperform | $12 → $10 | $2.14 | +367.29% | 9 | Jun 6, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $60 → $80 | $48.01 | +66.63% | 6 | Jun 3, 2024 | |
| ZURA Zura Bio | Maintains: Outperform | $16 → $21 | $3.43 | +512.24% | 2 | May 10, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $7 → $8 | $1.78 | +349.44% | 2 | May 7, 2024 | |
| PLRX Pliant Therapeutics | Reiterates: Outperform | $47 → $48 | $10.60 | +352.83% | 5 | May 7, 2024 | |
| CMMB Chemomab Therapeutics | Upgrades: Outperform | $6 | $0.97 | +519.20% | 6 | May 6, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $53 → $52 | $30.22 | +72.07% | 2 | May 3, 2024 | |
| ANTX AN2 Therapeutics | Reiterates: Perform | n/a | $2.13 | - | 3 | Apr 1, 2024 | |
| CLRB Cellectar Biosciences | Reiterates: Outperform | $11 → $12 | $2.38 | +404.20% | 2 | Mar 28, 2024 | |
| EVH Evolent Health | Initiates: Outperform | $45 | $19.25 | +133.77% | 1 | Mar 1, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Outperform | $120 | $1.66 | +7,128.92% | 3 | May 25, 2023 | |
| PMVP PMV Pharmaceuticals | Reiterates: Outperform | $15 | $1.57 | +855.41% | 5 | May 11, 2023 | |
| MBRX Moleculin Biotech | Reiterates: Outperform | $75 | $3.57 | +2,000.84% | 2 | Mar 24, 2023 | |
| EVAX Evaxion Biotech | Maintains: Outperform | $160 → $110 | $2.90 | +3,699.65% | 2 | Nov 17, 2022 |
Perspective Therapeutics
Jun 18, 2024
Reiterates: Outperform
Price Target: $2 → $19
Current: $10.49
Upside: +81.12%
Seres Therapeutics
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.70
Upside: -
Ventyx Biosciences
Jun 6, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $2.14
Upside: +367.29%
Corbus Pharmaceuticals Holdings
Jun 3, 2024
Maintains: Outperform
Price Target: $60 → $80
Current: $48.01
Upside: +66.63%
Zura Bio
May 10, 2024
Maintains: Outperform
Price Target: $16 → $21
Current: $3.43
Upside: +512.24%
Corvus Pharmaceuticals
May 7, 2024
Maintains: Outperform
Price Target: $7 → $8
Current: $1.78
Upside: +349.44%
Pliant Therapeutics
May 7, 2024
Reiterates: Outperform
Price Target: $47 → $48
Current: $10.60
Upside: +352.83%
Chemomab Therapeutics
May 6, 2024
Upgrades: Outperform
Price Target: $6
Current: $0.97
Upside: +519.20%
Kymera Therapeutics
May 3, 2024
Maintains: Outperform
Price Target: $53 → $52
Current: $30.22
Upside: +72.07%
AN2 Therapeutics
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $2.13
Upside: -
Cellectar Biosciences
Mar 28, 2024
Reiterates: Outperform
Price Target: $11 → $12
Current: $2.38
Upside: +404.20%
Evolent Health
Mar 1, 2024
Initiates: Outperform
Price Target: $45
Current: $19.25
Upside: +133.77%
Cyclacel Pharmaceuticals
May 25, 2023
Maintains: Outperform
Price Target: $120
Current: $1.66
Upside: +7,128.92%
PMV Pharmaceuticals
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.57
Upside: +855.41%
Moleculin Biotech
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $3.57
Upside: +2,000.84%
Evaxion Biotech
Nov 17, 2022
Maintains: Outperform
Price Target: $160 → $110
Current: $2.90
Upside: +3,699.65%